Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Apotex Health stock: key metrics at a glance
Apotex Health (TSX:APTX) slipped about 1.3% in the latest session to CA$28.60, drawing attention to how investors might weigh its current valuation, earnings profile, and business mix across generics, biosimilars, and branded products.
See our latest analysis for Apotex Health.
The 1 day share price return of 1.35% and year to date share price return of 5.93% suggest steady but not aggressive momentum, which fits with a stock where valuation and earnings quality are central to the story.
If you are weighing Apotex Health against other pharmaceutical opportunities, it can help to see how investors are pricing growth in healthcare artificial intelligence through our 6 healthcare AI stocks
With Apotex Health trading at CA$28.60 and an estimated intrinsic discount of about 54%, the key question is whether the stock is genuinely cheap or if the market already recognizes and prices in its future growth.
Preferred P/E of 17.5x: Is it justified?
Apotex Health trades on a P/E of 17.5x, which prices the stock above the broader North American pharmaceuticals industry average of 14.7x, even though our DCF estimate suggests it is trading at a 54% discount to intrinsic value at CA$28.60.
The P/E multiple compares the current share price to earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a diversified pharmaceutical group with conventional generics, specialty generics, and brands and biosimilars across Canada, the U.S., Mexico, and India, earnings tend to be a central yardstick because many investors focus on cash generation from an established product base.
The current P/E suggests the market is willing to pay a premium over the wider North American pharmaceuticals peer group. This may reflect the recent 146.4% earnings growth and net profit margin of 10.7%. At the same time, this premium sits against a backdrop of negative shareholders’ equity and a high level of debt, which makes it harder to rely on traditional balance sheet based ratios and shifts more attention to the sustainability and quality of earnings.
Compared with the sector average of 14.7x, Apotex Health’s 17.5x P/E is materially higher, implying investors are attaching more value to its earnings than they are to the typical North American pharmaceuticals stock.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Earnings of 17.5x (OVERVALUED).
However, this premium P/E sits alongside negative shareholders’ equity and sizeable debt, so any pressure on margins or cash flow could quickly challenge the current narrative.
Find out about the key risks to this Apotex Health narrative.
Another way to look at Apotex Health’s value
While the P/E of 17.5x makes Apotex Health look expensive relative to the North American pharmaceuticals average of 14.7x, the SWS DCF model presents a different perspective. It suggests the stock is trading about 54% below its estimated fair value of CA$62.18 per share.
That kind of gap can signal either a potential opportunity or that the market is pricing in risks the model does not fully capture. Which side do you think is closer to reality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Apotex Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 8 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
Next Steps
With mixed signals across valuation, earnings quality, and balance sheet strength, sentiment on Apotex Health is clearly divided. It makes sense to review the numbers for yourself and move quickly while the data is fresh, then weigh up the 2 key rewards and 4 important warning signs
Looking for more investment ideas?
If Apotex Health is on your radar, now is the moment to widen your watchlist with other carefully filtered opportunities before the market moves on without you.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include APTX.TO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
